Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
96 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Millennium Pharmaceuticals, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Millennium Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Millennium Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Millennium Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Millennium Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Millennium Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Millennium Pharmaceuticals, Inc.'s pipeline products Reasons to buy - Evaluate Millennium Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Millennium Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Millennium Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Millennium Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Millennium Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Millennium Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Millennium Pharmaceuticals, Inc. Snapshot 6 Millennium Pharmaceuticals, Inc. Overview 6 Key Information 6 Key Facts 6 Millennium Pharmaceuticals, Inc. - Research and Development Overview 7 Key Therapeutic Areas 7 Millennium Pharmaceuticals, Inc. - Pipeline Review 12 Pipeline Products by Stage of Development 12 Pipeline Products - Monotherapy 13 Pipeline Products - Partnered Products 14 Partnered Products/Combination Treatment Modalities 15 Pipeline Products - Out-Licensed Products 16 Out-Licensed Products/Combination Treatment Modalities 17 Millennium Pharmaceuticals, Inc. - Pipeline Products Glance 18 Millennium Pharmaceuticals, Inc. - Late Stage Pipeline Products 18 Pre-Registration Products/Combination Treatment Modalities 18 Filing rejected/Withdrawn Products/Combination Treatment Modalities 19 Phase III Products/Combination Treatment Modalities 20 Millennium Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 21 Phase II Products/Combination Treatment Modalities 21 Phase I Products/Combination Treatment Modalities 22 Millennium Pharmaceuticals, Inc. - Early Stage Pipeline Products 23 Preclinical Products/Combination Treatment Modalities 23 Discovery Products/Combination Treatment Modalities 24 Millennium Pharmaceuticals, Inc. - Drug Profiles 25 bortezomib 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 alisertib 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 brentuximab vedotin 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 ixazomib citrate 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 MLN-0128 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 MLN-2480 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 orteronel 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 MLN-0264 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 MLN-1117 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 MLN-7243 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 pevonedistat hydrochloride 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 TAK-659 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 TAK-733 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Small Molecules to Inhibit Histone Deacetylase 6 for Cacner 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Millennium Pharmaceuticals, Inc. - Pipeline Analysis 56 Millennium Pharmaceuticals, Inc. - Pipeline Products by Target 56 Millennium Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 58 Millennium Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 59 Millennium Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 60 Millennium Pharmaceuticals, Inc. - Recent Pipeline Updates 62 Millennium Pharmaceuticals, Inc. - Dormant Projects 89 Millennium Pharmaceuticals, Inc. - Discontinued Pipeline Products 90 Discontinued Pipeline Product Profiles 90 alisertib 90 betrixaban 90 bortezomib 90 HuL-2G7 91 orteronel 91 TAK-441 91 TAK-448 91 TAK-901 91 TAK-960 92 tandutinib 92 Millennium Pharmaceuticals, Inc. - Company Statement 93 Millennium Pharmaceuticals, Inc. - Locations And Subsidiaries 94 Head Office 94 Appendix 95 Methodology 95 Coverage 95 Secondary Research 95 Primary Research 95 Expert Panel Validation 95 Contact Us 96 Disclaimer 96
List of Tables Millennium Pharmaceuticals, Inc., Key Information 6 Millennium Pharmaceuticals, Inc., Key Facts 6 Millennium Pharmaceuticals, Inc. - Pipeline by Indication, 2014 9 Millennium Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 12 Millennium Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 13 Millennium Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014 14 Millennium Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 15 Millennium Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2014 16 Millennium Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 17 Millennium Pharmaceuticals, Inc. - Pre-Registration, 2014 18 Millennium Pharmaceuticals, Inc. - Filing rejected/Withdrawn, 2014 19 Millennium Pharmaceuticals, Inc. - Phase III, 2014 20 Millennium Pharmaceuticals, Inc. - Phase II, 2014 21 Millennium Pharmaceuticals, Inc. - Phase I, 2014 22 Millennium Pharmaceuticals, Inc. - Preclinical, 2014 23 Millennium Pharmaceuticals, Inc. - Discovery, 2014 24 Millennium Pharmaceuticals, Inc. - Pipeline by Target, 2014 57 Millennium Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 58 Millennium Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 59 Millennium Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 61 Millennium Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 62 Millennium Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 89 Millennium Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 90
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
